Guangdong Wannianqing released its 2026 half-year report. In the first half of the year, operating revenue was 145 million yuan, down 6.5% year on year, but net profit attributable to the parent turned from loss to profit, reaching 3.19 million yuan, compared with a loss of 7.22 million yuan in the same period last year. Net profit attributable to the parent after deducting non-recurring items also turned from loss to profit, reaching 160,000 yuan, compared with a loss of 10.74 million yuan in the same period last year. In the second quarter, the company's operating revenue was 78.58 million yuan, down 6.4% year on year, and net profit attributable to the parent was 6.5 million yuan, compared with a loss of 3.78 million yuan in the same period last year. Sales revenue from the company's health consumer products business reached 9.56 million yuan, up 176.72% year on year, and the net loss attributable to the parent narrowed by 43.83%. As of the end of the second quarter, the company's total assets were 908 million yuan and net assets attributable to the parent were 746 million yuan. The company holds 101 drug approval numbers, of which 32 are original innovative products, 10 are exclusive varieties, 4 are exclusive dosage forms, 16 are included in the national essential medicine list, and 38 are included in the national medical insurance list. It has also expanded its range of Chinese herbal medicine decoction pieces to 515 varieties.
Guangdong Lifestrong Pharmacy Co. Ltd.Guangdong Wannianqing's H1 net profit attributable to parent turned from a 7.22 million yuan loss to a 3.19 million yuan profit, with Q2 also swinging to a 6.5 million yuan profit.
